Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Tuesday 28 March, 2017

AstraZeneca PLC

Director/PDMR Shareholding

RNS Number : 7876A
AstraZeneca PLC
28 March 2017
 

28 March 2017 16:00 BST

 

TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announces that, on 28 March 2017, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) and of American Depositary Shares (ADSs) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP). Two ADSs are equivalent to one Ordinary Share.

 

The AZDBP award was granted on 28 March 2014, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2013 performance into Ordinary Shares or ADSs, and vested on completion of the three-year holding period.

 

The AZPSP award was granted on 28 March 2014. Following the application of performance measures specified at the time of grant, 92% of the AZPSP vested and the remaining unvested part immediately and irrevocably lapsed.

 

Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares and ADSs changed as detailed in the table below:

 

PDMR

Ordinary Shares acquired under the AZDBP

ADSs acquired under the AZDBP

Ordinary Shares acquired under the AZPSP

ADSs acquired under the AZPSP

Pascal Soriot

14,209


101,584


Marc Dunoyer

1,419


25,478


Mark Mallon


620


22,000

For tax purposes, the fair market value of an Ordinary Share at vest was 4974.5 pence and the fair market value of an ADS at vest was $31.80, being the relevant closing prices on the last trading day preceding the vesting day.

 

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

 

 

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Enquiries

 

 

 

 

 

Esra Erkal-Paler

UK/Global

+44 203 749 5638

Vanessa Rhodes

 

UK/Global

 

+44 203 749 5736

 

Karen Birmingham

 

UK/Global

 

+44 203 749 5634

 

Rob Skelding

 

UK/Global

 

+44 203 749 5821

 

Jacob Lund

 

Sweden

 

+46 8 553 260 20

 

Michele Meixell

 

US

 

+1 302 885 2677

 

Investor Relations



Thomas Kudsk Larsen

 

 

 

+44 203 749 5712

 

Craig Marks

 

Finance, Fixed Income, M&A

 

+44 7881 615 764

 

Henry Wheeler

 

Oncology

 

+44 203 749 5797

 

Mitchell Chan

 

Oncology

 

+1 240 477 3771

 

Lindsey Trickett

 

Cardiovascular & Metabolic Diseases

 

+1 240 543 7970

 

Nick Stone

 

Respiratory

 

+44 203 749 5716

 

Christer Gruvris

Autoimmunity, Neuroscience & Infection

+44 203 749 5711

US toll free


+1 866 381 7277

 

 

Adrian Kemp

Company Secretary, AstraZeneca PLC

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Pascal Soriot

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Acquisition of ordinary shares pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

0

115,793

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

28 March 2017

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Marc Dunoyer

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of US$0.25 each in AstraZeneca PLC

 

 

GB0009895292

 

b)

 

Nature of the transaction

 

 

Acquisition of ordinary shares pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

0

26,897

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

28 March 2017

f)

 

Place of the transaction

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Mark Mallon

2

 

Reason for the notification

 

a)

 

Position/status

 

Person Discharging Managerial Responsibilities

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

AstraZeneca PLC

b)

 

LEI

PY6ZZQWO2IZFZC3IOL08

4i

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

AstraZeneca PLC American Depositary Shares

 

  

CUSIP: 046353108

b)

 

Nature of the transaction

 

 

Acquisition of ADSs pursuant to vestings under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan, for nil consideration.

c)

 

Price(s) and volume(s)

 

 

Price(s)

Volume(s)

0

22,620

d)

 

Aggregated information

 

- Aggregated volume

- Price

 

Not applicable - single transaction

e)

 

Date of the transaction

 

28 March 2017

f)

 

Place of the transaction

 

Outside a trading venue

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHUWSORBNAOUAR

a d v e r t i s e m e n t